Evidence map›Paper›PMID 40713707›Full record

ArticleAlzheimer's research & therapy2025

Alcohol consumption and cerebrospinal fluid biomarkers for preclinical alzheimer's disease in a population-based sample of 70-year-olds.

Silke Kern, Tobias Skillbäck, Henrik Zetterberg, Anna Dittrich, Felicia Ahlner, Anna Zettergren, Margda Waern, Nazib M Seidu, Ulf Andreasson, Kaj Blennow and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Silke Kern *Department of Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.
Tobias Skillbäck *Department of Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden. tobias.skillback@gu.se.
Henrik ZetterbergClinical Neurochemistry Laboratory Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.
Anna DittrichDepartment of Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.
Felicia AhlnerDepartment of Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.
Anna ZettergrenDepartment of Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.
Margda WaernDepartment of Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.
Nazib M SeiduDepartment of Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.
Ulf AndreassonClinical Neurochemistry Laboratory Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.
Kaj BlennowClinical Neurochemistry Laboratory Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.
Ingmar SkoogDepartment of Neuropsychiatric Epidemiology Unit, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Wallinsgatan 6, Mölndal, 43141, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt is largely unknown how alcohol use affects the risk of Alzheimer`s disease (AD). Therefore, studies on the influence of alcohol use on cerebrospinal fluid (CSF) biomarkers for the earliest preclinical phase of AD are needed.

methodsThis was a cross-sectional cohort study. The sample (n = 301) was derived from the 2014-2016 examinations of the Gothenburg H70 Birth Cohort Studies. The study cohort consisted of 301 70-year-old women and men, where of 246 cognitively unimpaired and 55 with mild cognitive deficits. Information on alcohol consumption (g/week and type of alcohol) was collected and CSF amyloid-β

resultsThere were no correlations between weekly alcohol consumption and any of the CSF markers studied in the total sample of cognitively unimpaired participants (n = 246). After adjustments for multiplicity with FDR, there was an association between white wine and Ng in women with CDR = 0 (β:0.254, CI: ( 0.069: 0.439), p = 0.0076, FDR = 0.0455). Interaction analysis between female sex and red wine intake was a significant predictor of high Ng levels (β:0.410, CI: ( 0.099: 0.721), p = 0.0100, FDR = 0.0500). There were no correlations between consumption of specific types of alcohol (spirits, white wine, red wine, fortified wine, and beer) and any of the biomarkers studied in the total sample of cognitively unimpaired participants.

conclusionsOur findings indicate that higher alcohol use in older cognitively unimpaired women correlates with a biomarker of synaptic dysfunction in AD, which is an important observation in a time when alcohol use is increasing among women.

Indexed as

Alcohol DrinkingAlzheimer DiseaseAgedAmyloid beta-PeptidesBiomarkersCognitive DysfunctionCohort StudiesCross-Sectional StudiesFemaleHumansMaleNeurofilament ProteinsNeurograninPeptide Fragmentstau ProteinsAmyloid beta-Peptidesamyloid beta-protein (1-42)BiomarkersMAPT protein, humanneurofilament protein LNeurofilament ProteinsNeurograninPeptide Fragmentstau ProteinsAlcohol consumptionAlzheimer’s diseaseAβ42BiomarkersCerebrospinal fluidNeurograninNfLP-tauT-tau

Identifiers

PMID40713707
PMCPMC12291311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.